Cargando…

Evaluation of antibody response against recombinant domain III proteins of dengue virus type 1 and 2

Dengue, a mosquito borne viral disease caused by dengue virus has emerged as a major health problem during the last few decades. The envelope domain III (DIII) protein of dengue virus is highly immunogenic and capable of inducing neutralizing antibodies against wild-type dengue virus. The envelope d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tripathi, Nagesh K, Shrivastava, Ambuj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AIMS Press 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6605013/ https://www.ncbi.nlm.nih.gov/pubmed/31294159 http://dx.doi.org/10.3934/microbiol.2017.2.248

Ejemplares similares

Recent Developments in Recombinant Protein–Based Dengue Vaccines
por: Tripathi, Nagesh K., et al.
Publicado: (2018)

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development
por: Tripathi, Nagesh K., et al.
Publicado: (2019)

Dengue virus type-3 envelope protein domain III; expression and immunogenicity
por: Fahimi, Hossein, et al.
Publicado: (2014)

Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III
por: Matsui, Kiyohiko, et al.
Publicado: (2010)

DNA Vaccines against Dengue Virus Type 2 Based on Truncate Envelope Protein or Its Domain III
por: Azevedo, Adriana S., et al.
Publicado: (2011)

Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice
por: Chen, Mei-Yu, et al.
Publicado: (2020)

Development and evaluation of one step single tube multiplex RT-PCR for rapid detection and typing of dengue viruses
por: Saxena, Parag, et al.
Publicado: (2008)

A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III
por: Hu, Dan, et al.
Publicado: (2019)

Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice
por: Kulkarni, Ajit, et al.
Publicado: (2017)

In silico binding analysis of lutein and rosmarinic acid against envelope domain III protein of dengue virus
por: Panchal, Ritesh, et al.
Publicado: (2021)

Diagnostic Performance of Dengue Virus Envelope Domain III in Acute Dengue Infection
por: Nguyen, Ngoc Minh, et al.
Publicado: (2019)

Casamino acids facilitate the secretion of recombinant dengue virus serotype-3 envelope domain III in Pichia pastoris
por: Kaushik, Neha, et al.
Publicado: (2016)

Phage Display Approaches for the Isolation of Monoclonal Antibodies Against Dengue Virus Envelope Domain III from Human and Mouse Derived Libraries
por: Moreland, Nicole J., et al.
Publicado: (2012)

Development of nsP2 protease based cell free high throughput screening assay for evaluation of inhibitors against emerging Chikungunya virus
por: Saha, Amrita, et al.
Publicado: (2018)

Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein
por: Budigi, Yadunanda, et al.
Publicado: (2018)

Antibodies Against Modified NS1 Wing Domain Peptide Protect Against Dengue Virus Infection
por: Lai, Yen-Chung, et al.
Publicado: (2017)

Dengue virus 4/2 envelope domain chimeric virus panel maps type-specific responses against dengue serotype 2
por: Zhu, Deanna R., et al.
Publicado: (2023)

Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies
por: Tripathi, Lav, et al.
Publicado: (2015)

Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice
por: Chiang, Chen-Yi, et al.
Publicado: (2016)

Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity
por: Park, Jisang, et al.
Publicado: (2020)

Development of Multispecies Recombinant Nucleoprotein-Based Indirect ELISA for High-Throughput Screening of Crimean-Congo Hemorrhagic Fever Virus-Specific Antibodies
por: Shrivastava, Neha, et al.
Publicado: (2019)

Chimeric flavivirus enables evaluation of antibodies against dengue virus envelope protein in vitro and in vivo
por: Kurosu, Takeshi, et al.
Publicado: (2020)

Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes
por: Poggianella, Monica, et al.
Publicado: (2015)

Emergence of genotype Cosmopolitan of dengue virus type 2 and genotype III of dengue virus type 3 in Thailand
por: Phadungsombat, Juthamas, et al.
Publicado: (2018)

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
por: Harahap-Carrillo, Indira S., et al.
Publicado: (2015)

Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein
por: Tang, Chung-Tao, et al.
Publicado: (2015)

Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies
por: Poddar, Ankur, et al.
Publicado: (2016)

Multiple recombinant dengue type 1 viruses in an isolate from a dengue patient
por: Aaskov, John, et al.
Publicado: (2007)

New dengue virus Type-1 strain; recombinant DEN1 protein expression; potential in recombinant vaccine construction, virus detection and dengue fever diagnosis and therapy
Publicado: (1994)

Dengue Mosaic Vaccines Enhance Cellular Immunity and Expand the Breadth of Neutralizing Antibody Against All Four Serotypes of Dengue Viruses in Mice
por: Hou, Jue, et al.
Publicado: (2019)

Recombinant Dengue virus protein NS2B alters membrane permeability in different membrane models
por: León-Juárez, Moisés, et al.
Publicado: (2016)

Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4(+) T Cells to the Dengue Virus Envelope Protein Domain III
por: Zaneti, Arthur Baruel, et al.
Publicado: (2019)

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
por: Arora, Upasana, et al.
Publicado: (2012)

A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies
por: Chua, Anthony JS, et al.
Publicado: (2013)

Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine
por: Simmons, Monika, et al.
Publicado: (2016)

DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection
por: Slon Campos, Jose L., et al.
Publicado: (2017)

Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III
por: Ji, Guang-Hui, et al.
Publicado: (2015)

Lipidated Dengue-2 Envelope Protein Domain III Independently Stimulates Long-Lasting Neutralizing Antibodies and Reduces the Risk of Antibody-Dependent Enhancement
por: Chiang, Chen-Yi, et al.
Publicado: (2013)

Molecular Changes in Dengue Envelope Protein Domain III upon Interaction with Glycosaminoglycans
por: Hyatt, James G., et al.
Publicado: (2020)

Production of recombinant nonstructural 1 protein in Escherichia coli for early detection of Japanese encephalitis virus infection
por: Tripathi, Nagesh K., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_aqlg4174csfbn474vhnvtpvdgq